It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Jennifer G. Goldman, MD, MS

Patient Feedback
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Associate Professor
Medical or Graduate Education: Northwestern University Feinberg School of Medicine
Residency: Washington University School of Medicine - Neurology
Fellowship: Rush University Medical Center - Movement Disorders
Clinical Expertise:
  • Ataxia
  • Balance disorders
  • Botulinum toxin injections
  • Cervical dystonia
  • Chorea
  • Corticobasal degeneration
  • Dementia and degenerative disease
  • Dystonia
  • Essential tremor
  • Hemifacial spasm
  • Huntington's disease
  • Movement disorders
  • Multiple system atrophy
  • Myoclonus
  • Parkinson's disease
  • Parkinsonism
  • Progressive supranuclear palsy
  • Restless legs syndrome (RLS)
  • Stiff-person syndrome
  • Tics
  • Tremor
  • Wilson disease
  • Writer's cramp
Research Interests:
  • Cognition and dementia in Parkinson disease and parkinsonian disorders
  • Neuropsychiatric features of Parkinson disease and parkinsonian disorders
  • Dementia with Lewy bodies
  • Neuroimaging and cognition and hallucinations in Parkinson disease and parkinsonian disorders
  • Genetics of hallucinations in Parkinson disease
  • Occupational dystonia, including musician's dystonia
  • Clinical trials in Parkinson disease
  • Ataxia
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Writer's cramp.
    Goldman JG
    2015 Sep 21
  2. Advances in the treatment of cognitive impairment in Parkinson's disease.
    Goldman JG, Weintraub D
    Mov. Disord.
    2015 Sep 15
  3. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial.
    David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldman JG, Comella CL, Vaillancourt DE, Corcos DM
    Mov. Disord.
    2015 Oct
  4. Clinical Impact of an Antimicrobial Stewardship Program on Pediatric Hospitalist Practice, a 5-Year Retrospective Analysis.
    McCulloh RJ, Queen MA, Lee B, Yu D, Stach L, Goldman J, Myers A, Pate B, Newland JG
    Hosp Pediatr
    2015 Oct
  5. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J, White JR
    Ann Pharmacother
    2015 Oct
  6. Cognitive profile of LRRK2-related Parkinson's disease.
    Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP
    Mov. Disord.
    2015 Feb 4
  7. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.
    Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP
    Mov. Disord.
    2015 Aug 21
  8. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing.
    Barton BR, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG
    Mov. Disord.
    2014 May 13
  9. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease.
    Chu Y, Goldman JG, Kelly L, He Y, Waliczek T, Kordower JH
    Neurobiol. Dis.
    2014 May 10
  10. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.
    Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG
    2014 Mar
    137(Pt 3):849-59.
  11. Treatment of psychosis and dementia in Parkinson's disease.
    Goldman JG, Holden S
    Curr Treat Options Neurol
    2014 Mar
  12. Functional Brain Activity Relates to 0-3 and 3-8 Hz Force Oscillations in Essential Tremor.
    Neely KA, Kurani AS, Shukla P, Planetta PJ, Wagle Shukla A, Goldman JG, Corcos DM, Okun MS, Vaillancourt DE
    Cereb. Cortex
    2014 Jun 24
  13. Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable.
    Eberling J, Vincent L, Goldman JG, Weintraub D, Kulisevsky J, Marras C, Stebbins G, Kieburtz K
    J Parkinsons Dis
    2014 Jul 2
  14. Parkinson's disease mild cognitive impairment: application and validation of the criteria.
    Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Tröster AI, Burn DJ, Litvan I
    J Parkinsons Dis
    2014 Jan 1
  15. Diagnosing PD-MCI by MDS task force criteria: How many and which neuropsychological tests?
    Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT
    Mov. Disord.
    2014 Dec 1
  16. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS.
    Goldman JG, Stebbins GT, Leung V, Tilley BC, Goetz CG
    Parkinsonism Relat. Disord.
    2014 Aug 13
  17. Premotor and nonmotor features of Parkinson's disease.
    Goldman JG, Postuma R
    Curr. Opin. Neurol.
    2014 Aug
  18. The spectrum of cognitive impairment in Lewy body diseases.
    Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE
    Mov. Disord.
    2014 Apr 15
  19. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.
    Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT
    Mov. Disord.
    2013 Oct 9
  20. Inpatients with schizophrenia report impaired situational motivation but intact global and social motivation.
    Trémeau F, Goldman J, Antonius D, Javitt DC
    Psychiatry Res
    2013 Nov 30
  21. Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation.
    Goldman JG, Eichenseer SR, Berry-Kravis E, Zimnowodzki S, Gregory A, Hogarth P, Hayflick SJ.
    Mov Disord. 2013
    2013 Mar 13. doi: 10.1002/mds.25410. [Epub ahead of print] No abstract available.
  22. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease.
    Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT.
    Parkinsonism Relat Disord. 2013
    2013 Jun 2. doi:pii: S1353-8020(13)00193-4. 10.1016/j.parkreldis.2013.05.006. [Epub ahead of print]
  23. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging.
    Goetz CG, Vaughan CL, Goldman JG, Stebbins GT.
    Mov Disord. 2013
    2013 Jul 10. doi: 10.1002/mds.25554. [Epub ahead of print]
  24. New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN.
    Hogarth P, Gregory A, Kruer MC, Sanford L, Wagoner W, Natowicz MR, Egel RT, Subramony SH, Goldman JG, Berry-Kravis E, Foulds NC, Hammans SR, Desguerre I, Rodriguez D, Wilson C, Diedrich A, Green S, Tran H, Reese L, Woltjer RL, Hayflick SJ.
    Neurology. 2013
    2013 Jan 15
    80(3):268-275. Epub 2012 Dec 26.
  25. Two in one: report of a patient with spinocerebellar ataxia types 2 and 10.
    Kapur SS, Goldman JG.
    Arch Neurol. 2012
    2012 Sep 1
    69(9):1200-3. doi: 10.1001/archneurol.2011.3044.
  26. Spinocerebellar ataxia types 2 and 10: more than a coincidental association?-Reply.
    Kapur SS, Goldman JG.
    Arch Neurol. 2012
    2012 Nov 1
    69(11):1524-5. doi: 10.1001/archneurol.2012.2771. No abstract available.
  27. Spinocerebellar ataxia types 2 and 10: more than a coincidental association?-Reply.
    Kapur SS, Goldman JG.
    Arch Neurol. 2012
    2012 Nov
    69(11):1524-5. doi: 10.1001/archneurol.2012.2771. No abstract available.
  28. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia.
    Goldman JG, Stebbins GT, Bernard B, Stoub TR, Goetz CG, deToledo-Morrell L.
    Mov Disord. 2012
    2012 May
    27(6):727-34. doi: 10.1002/mds.24938. Epub 2012 Mar 12.
  29. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.
    Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M.
    Mov Disord. 2012
    2012 Mar
    27(3):349-56. doi: 10.1002/mds.24893. Epub 2012 Jan 24. Review.
  30. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia.
    Barton B, Grabli D, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG.
    Mov Disord. 2012
    2012 Feb
    27(2):248-53. doi: 10.1002/mds.24059. Epub 2011 Dec 9.
  31. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.
    Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG.
    Mov Disord. 2012
    2012 Aug
    27(9):1129-36. doi: 10.1002/mds.25062. Epub 2012 Jul 6.
  32. Pediatric Crohn disease presenting as appendicitis: differentiating features from typical appendicitis.
    Bass JA, Goldman J, Jackson MA, Gasior AC, Sharp SW, Drews AA, Saunders CJ, St Peter SD
    Eur J Pediatr Surg
    2012 Aug
  33. An update expert opinion on management and research strategies in Parkinson's disease psychosis.
    Goldman JG, Vaughan CL, Goetz CG.
    Expert Opin Pharmacother. 2011
    2011 Sep
    12(13):2009-24. doi: 10.1517/14656566.2011.587122. Epub 2011 Jun 2. Review.
  34. Combined measures of movement and force variability distinguish Parkinson's disease from essential tremor.
    Poon C, Robichaud JA, Corcos DM, Goldman JG, Vaillancourt DE.
    Clin Neurophysiol. 2011
    2011 Nov
    122(11):2268-75. doi: 10.1016/j.clinph.2011.04.014. Epub 2011 May 13.
  35. New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.
    Goldman JG.
    Parkinsons Dis. 2011
    2011 Mar 2
    2011:675630. doi: 10.4061/2011/675630.
  36. Development of biomarkers to optimize pediatric patient management: what makes children different?
    Goldman J, Becker ML, Jones B, Clements M, Leeder JS
    Biomark Med
    2011 Dec
  37. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.
    Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Tröster AI, Weintraub D.
    Mov Disord. 2011
    2011 Aug 15
    26(10):1814-24. doi: 10.1002/mds.23823. Epub 2011 Jun 9. Review.
  38. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations.
    Goldman JG, Marr D, Zhou L, Ouyang B, Leurgans SE, Berry-Kravis E, Goetz CG.
    Mov Disord. 2011
    2011 Aug 1
    26(9):1781-2. doi: 10.1002/mds.23655. Epub 2011 Apr 19. No abstract available.
  39. A recommended scale for cognitive screening in clinical trials of Parkinson's disease.
    Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY; Parkinson Study Group Cognitive/Psychiatric Working Group.
    Mov Disord. 2010
    2010 Nov 15
    25(15):2501-7. doi: 10.1002/mds.23362.
  40. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies.
    Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT.
    Mov Disord. 2008
    2008 Nov 15
    23(15):2248-50. doi: 10.1002/mds.22322.
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.